(MENAFN- PR Newswire)
NEW YORK, Oct. 13, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The Global Gastrointestinal Diseases Therapeutics Market
size is estimated to grow by USD 18.5 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of
6.81%
during the forecast period. Increasing incidence of gastrointestinal diseases
is driving market growth,
with a trend towards
availability of nutritional therapies. However,
high cost of gastrointestinal therapeutics
poses a challenge - Key market players include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corp., Eisai Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Olympus Corp., Ovesco Endoscopy AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and UCB SA.
Continue Reading
Technavio has announced its latest market research report titled Global gastrointestinal diseases therapeutics market 2024-2028
AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now
| Forecast period |
2024-2028 |
| Base Year |
2023 |
| Historic Data |
2017 - 2021 |
| Segment Covered |
Drug Class (Anti-inflammatory and immunosuppressors, Acid neutralizers, and Others), Type (Branded and Generics), and Geography (North America, Asia, Europe, and Rest of World (ROW)) |
| Region Covered |
North America, Asia, Europe, and Rest of World (ROW) |
| Key companies profiled |
Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corp., Eisai Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Olympus Corp., Ovesco Endoscopy AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and UCB SA |
Key Market Trends Fueling Growth
Gastrointestinal diseases, such as irritable bowel syndrome (IBS) and celiac disease, require effective therapeutic approaches to manage symptoms and improve patients' quality of life. Nutritional therapies, including specialized diets and dietary supplements, play a significant role in this regard. For instance, the low-FODMAP diet, which restricts fermentable carbohydrates, can help manage IBS symptoms. Patients with celiac disease or non-celiac gluten sensitivity must adhere to a strict gluten-free diet, with the availability of certified gluten-free products and clear labeling being essential. Omega-3 fatty acids found in fish oil supplements have shown potential benefits for inflammatory bowel disease (IBD) patients. Malnutrition is a common risk for those with chronic gastrointestinal diseases, necessitating medical foods and oral nutritional supplements. The availability of these nutritional therapies complements pharmaceutical treatments, reducing symptom severity and improving overall quality of life, thereby driving market growth in the gastrointestinal diseases therapeutics sector during the forecast period.
The gastrointestinal diseases therapeutics market is experiencing significant growth due to the rising prevalence of chronic digestive conditions like Gastroesophageal Reflux Disease (GERD), Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), and Gastrointestinal cancers. Autoimmune diseases such as Type 1 diabetes, Multiple Sclerosis, Rheumatoid Arthritis , Lupus, Crohn's disease, Psoriasis, and Scleroderma also contribute to the market's expansion. Clinical trials for novel therapies and targeted drugs, including Inflectra, Remicade, Renflexis, Tysabri, Ustekinumab, Risankizumab, TNF blockers, and Zeposia, are driving innovation. Market trends include the use of telemedicine, biologics, Proton Pump Inhibitors (PPIs), Aminosalicylates, Antacids, Laxatives, H2 antagonists, and H1 antagonists. Hospital pharmacies, drug stores, retail pharmacies, and online providers are key distribution channels for GI drugs. Patent expirations and the entry of biosimilars are expected to impact market dynamics.
Insights on how AI is driving innovation, efficiency, and market growth- Request Sample!
Market
Challenges
Gastrointestinal diseases, such as ulcerative colitis and Crohn's disease, require ongoing treatment to manage symptoms and prevent complications, including cancer. Biologics and small molecules are commonly used therapies. For instance, infliximab (Remicade, Johnson & Johnson) and vedolizumab (Entyvio, Takeda Pharmaceutical) are biologic drugs used for chronic gastrointestinal diseases, with average costs ranging from USD6,000 to USD8,700. Xeljanz oral tablets (Pfizer) for ulcerative colitis cost around USD4,900 to USD5,000 for 60 tablets. Physicians often prescribe steroids and biologics for moderate to severe chronic gastrointestinal diseases. The average monthly cost of biologics for IBD is between USD2,500 and USD5,500. However, rising out-of-pocket expenses for these therapies and procedures may hinder the growth of the global gastrointestinal diseases therapeutics market. The average treatment costs for ulcerative colitis are USD6,000 to USD12,000, and for Crohn's disease, they are USD30,000 to USD32,000. These costs primarily consist of medication, doctor fees, and hospital visits or stays.
The gastrointestinal diseases therapeutics market faces significant challenges from various quarters. Biologics, such as Inflectra, Remicade, Renflexis, Tysabri, Ustekinumab, Risankizumab, and TNF blockers, dominate the market for chronic digestive diseases like ulcerative proctitis, IBS, Crohn's disease, and others. However, patent expirations pose a threat, leading to the entry of biosimilars. Proton pump inhibitors, H2 antagonists, aminosalicylates, antacids, and laxatives continue to be popular in hospital pharmacies, drug stores, retail pharmacies, and online providers. The injectable segment, including drugs like Humira, Adalimumab, Certolizumab, Infliximab, and Natalizumab, is growing rapidly. OTC drugs , such as anti-emetics and laxative preparations, are also gaining traction in the market. Novel therapies and targeted drugs offer promising opportunities for innovation. However, the market is competitive, with various players vying for market share.
Insights into how AI is reshaping industries and driving growth-
Download a Sample Report
Segment Overview
This gastrointestinal diseases therapeutics market report extensively covers market segmentation by
Drug Class
1.1 Anti-inflammatory and immunosuppressors
1.2 Acid neutralizers
1.3 Others
Type
Geography
3.1 North America
3.2 Asia
3.3 Europe
3.4 Rest of World (ROW)
1.1
Anti-inflammatory and immunosuppressors-
The global gastrointestinal diseases therapeutics market is experiencing significant growth, particularly in the anti-inflammatory and immunosuppressors segment. This segment's expansion is driven by the rising prevalence of inflammatory bowel diseases (IBDs) such as ulcerative colitis and Crohn's disease. IBDs are chronic conditions characterized by inflammation in the digestive tract, leading to moderate to severe abdominal pain. Anti-inflammatory drugs, including corticosteroids and nonsteroidal options, are commonly used to alleviate inflammation and pain in patients with IBDs. Bausch Health Companies Inc. And Merck are prominent players in the market, offering Colazal (balsalazide disodium) and various 5-aminosalicylic acid (5-ASA) drugs, respectively. 5-ASA is a major therapeutic class used to block the production of inflammatory substances in the initial stages of IBD treatment. Immunosuppressors, like azathioprine, mercaptopurine, tofacitinib, and cyclosporine, are another essential class of drugs that suppress the immune response to inflammation. Pfizer's XELJANZ (tofacitinib) is an immunosuppressor used for ulcerative colitis treatment. Biologics, such as TNF inhibitors, anti-integrin, anti-interleukin-12, and interleukin-23 therapies, are also gaining popularity for their effectiveness in reducing inflammatory symptoms among Crohn's disease and ulcerative colitis patients. The presence of these drugs in the market is expected to fuel the growth of the anti-inflammatory and immunosuppressors segment and the gastrointestinal diseases therapeutics market as a whole during the forecast period.
Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2017 - 2021)
Research Analysis
The Gastrointestinal (GI) diseases therapeutics market encompasses a range of disorders that affect the digestive system, including gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), gastrointestinal cancers, autoimmune diseases such as Type 1 diabetes , Multiple sclerosis, Rheumatoid arthritis, Lupus, Crohn's disease, Psoriasis, and Scleroderma, among others. These chronic digestive diseases impact millions of people worldwide, leading to significant morbidity and mortality. Current therapies include GI drugs, which provide symptomatic relief, and novel therapies such as targeted drugs that address the underlying causes of these conditions. The market for GI therapeutics is expected to grow significantly due to the increasing prevalence of these diseases and the development of new and innovative treatments.
Market Research Overview
The Gastrointestinal (GI) diseases therapeutics market encompasses a range of conditions including Gastroesophageal Reflux Disease (GERD), Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Gastrointestinal cancers, Autoimmune diseases such as Type 1 diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Lupus, Crohn's disease, Psoriasis, and Scleroderma, among others. Therapeutic options for these chronic digestive diseases include Clinical trials, Telemedicine, Biologics, Proton pump inhibitors, Aminosalicylates, Antacids, Laxatives, H2 antagonists, Peptic ulcer disease treatments for Gastric ulcer and Duodenal ulcer, and Hospital pharmacies, Drug stores, Retail pharmacies, and Online providers. Novel therapies and targeted drugs like Inflectra, Remicade, Renflexis, Tysabri, Ustekinumab, Risankizumab, TNF blockers, Zeposia, and others are transforming the treatment landscape. Patent expirations and the emergence of Biosimilars are impacting the market dynamics, while Linzess, Humira, Adalimumab, Certolizumab, Infliximab, Natalizumab, and other key players dominate the market. The market also includes the Injectable segment and Over-the-counter (OTC) drugs, Anti-emetics, and Laxative preparations, available through Online pharmacies.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
Drug Class
Anti-inflammatory And Immunosuppressors
Acid Neutralizers
Others
Type
Geography
North America
Asia
Europe
Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:
[email protected]
Website:
SOURCE Technavio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN13102024003732001241ID1108774535